• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2014.

Cover of GeneReviews®

GeneReviews® [Internet].

Show details

Craniometaphyseal Dysplasia, Autosomal Dominant

Synonyms: CMDJ; Craniometaphyseal Dysplasia, Jackson Type

, PhD and , DDS, MS, PhD.

Author Information
, PhD
Assistant Professor, Department of Reconstructive Sciences
Center for Regenerative Medicine and Skeletal Development
University of Connecticut Health Center (UCHC)
Farmington, Connecticut
, DDS, MS, PhD
Department of Oral Health and Diagnostic Sciences
University of Connecticut Health Center (UCHC)
Farmington, Connecticut

Initial Posting: ; Last Update: November 2, 2010.

Summary

Disease characteristics. Autosomal dominant craniometaphyseal dysplasia (designated AD-CMD in this review) is characterized by progressive diffuse hyperostosis of cranial bones evident clinically as wide nasal bridge, paranasal bossing, wide-set eyes with an increase in bizygomatic width, and prominent mandible. Development of dentition may be delayed and teeth may fail to erupt as a result of hyperostosis and sclerosis of alveolar bone. Progressive thickening of craniofacial bones continues throughout life, often resulting in narrowing of the cranial foramina, including the foramen magnum. If untreated, compression of cranial nerves can lead to disabling conditions such as facial palsy, blindness, or deafness (conductive and/or sensorineural hearing loss). In individuals with typical uncomplicated AD-CMD life expectancy is normal; in those with severe AD-CMD life expectancy can be reduced as a result of compression of the foramen magnum.

Diagnosis/testing. Diagnosis is based on clinical and radiographic findings that include diffuse hyperostosis of the cranial base, cranial vault, facial bones, and mandible and metaphyseal widening and radiolucency in the long bones. ANKH is the only gene known to be associated with AD-CMD. Mutations in other as-yet unknown genes may also be causative.

Management. Treatment of manifestations: Treatment consists primarily of surgery to reduce compression of cranial nerves and the brain stem/spinal cord at the level of the foramen magnum. Severely overgrown facial bones can be contoured; however, surgical procedures can be technically difficult and bone regrowth is common.

Surveillance: Regular neurologic evaluation, hearing assessment, and ophthalmologic examination, at intervals determined by the individual's history and severity of skeletal changes.

Genetic counseling. AD-CMD is inherited in an autosomal dominant manner. Many individuals with AD-CMD caused by a mutation in ANKH have an affected parent, but de novo mutations are frequent in simplex cases (i.e., a single occurrence in a family). Each child of an individual with AD-CMD has a 50% chance of inheriting the mutation. Prenatal testing for pregnancies at increased risk for AD-CMD is possible if the disease-causing mutation in the family is known.

Diagnosis

Clinical Diagnosis

Diagnosis of autosomal dominant craniometaphyseal dysplasia (AD-CMD) is based on clinical and radiographic findings [Jackson et al 1954, Gorlin et al 2001].

Obstruction of the nasal sinuses, sclerosis of the cranial base, and flaring of long bone metaphyses may be observed within the first weeks of life.

Clinical Manifestations

Facial features include wide nasal bridge, paranasal bossing, wide-set eyes (ocular hypertelorism) with an increase in bizygomatic width, and prominent mandible (Figure 1).

Figure 1

Figure

Figure 1. Facial features of a 13-year-old girl with AD-CMD

Reprinted from Reichenberger et al [2001], with permission from Elsevier

Long skull shape (dolichocephaly) resulting from fronto-occipital hyperostosis has been reported in a number of individuals.

Radiographic Manifestations

Cranial radiographs. Typical findings:

  • Beginning sclerosis of the cranial base at early stages, sometimes detected in infants [Taylor & Sprague 1989] (Figure 2)
  • Increasing diffuse hyperostosis of the cranial base, cranial vault, facial bones, and mandible as the condition progresses [Lamazza et al 2009]
Figure 2

Figure

Figure 2. Increased thickness of craniofacial bones in three-year-old with AD-CMD

Other findings variably present:

Long bone radiographs. The long bone phenotype, consisting of metaphyseal widening (described as Erlenmeyer flask- or club-shaped) with thinned cortex and decreased bony density (radiolucency) in the metaphyses, can be detected early in life. Metaphyseal changes typically develop during early childhood. The flaring is most prominently seen in the distal femur and tibia (Figure 3).

Figure 3

Figure

Figure 3. Metaphyseal widening of long bones, specifically prominent at the knee joint

Ribs and the medial (endochondral) portion of the clavicles can be sclerotic in younger children but show normal bone density by age five years [Richards et al 1996].

Diaphyseal sclerosis/hyperostosis can be present in infancy but disappears with age. Bone density of the diaphyses is normal in children and adults; cortical thickness can be increased.

Testing

Blood calcium and phosphate concentrations are within normal limits [Cheung et al 1997] or decreased [Fanconi et al 1988, Sheppard et al 2003].

Serum alkaline phosphatase activity can be elevated [Fanconi et al 1988, Cheung et al 1997, Sheppard et al 2003].

Parathyroid hormone level is normal or can be slightly/transiently elevated [Fanconi et al 1988, Cheung et al 1997, Sheppard et al 2003].

Osteocalcin is decreased [Yamamoto et al 1993].

Note: Findings are based on very limited data. Variability of the described parameters can be expected. Abnormal parameters may be transient.

Molecular Genetic Testing

Gene. Mutations have been found in the human ankylosis gene (ANKH) for autosomal dominant CMD and some simplex cases (i.e., a single occurrence in a family) [Nurnberg et al 2001, Reichenberger et al 2001].

Other loci. Some simplex cases of CMD did not have identifiable mutations in ANKH, suggesting possible locus heterogeneity.

Clinical testing

Table 1. Summary of Molecular Genetic Testing Used in Autosomal Dominant Craniometaphyseal Dysplasia (AD-CMD)

Gene Symbol Test MethodMutations DetectedMutation Detection Frequency by Test Method 1
ANKHSequence analysisSequence variants 2~90% 3

1. The ability of the test method used to detect a mutation that is present in the indicated gene

2. Examples of mutations detected by sequence analysis may include small intragenic deletions/insertions and missense, nonsense, and splice site mutations.

3. Proportion of affected individuals in whom a mutation in ANKH is usually found [Nurnberg et al 2001, Reichenberger et al 2001]

Interpretation of test results. For issues to consider in interpretation of sequence analysis results. click here.

Testing Strategy

To confirm/establish the diagnosis in a proband

  • Clinical examination and cranial and long bone radiographs (distal third of the femur) to identify characteristic findings
  • Molecular genetic testing of ANKH to confirm the diagnosis

Prenatal diagnosis and preimplantation genetic diagnosis (PGD) for at-risk pregnancies require prior identification of the disease-causing mutation in the family.

Clinical Description

Natural History

Autosomal dominant craniometaphyseal dysplasia (AD-CMD) is often detected within the first few weeks of life because of breathing or feeding problems resulting from choanal stenosis (narrowing of nasal sinus) [Haverkamp et al 1996, Cheung et al 1997].

Early stages of AD-CMD can be radiographically recognized as sclerosis of the cranial base. Hyperostosis of the cranial base, cranial vault, facial bones, and mandible occurs gradually. Overgrowth of the lower jaw (mandibular hyperostosis) and recessed midface are often seen [Hayashibara et al 2000].

Progressive thickening of craniofacial bones continues throughout life, often resulting in narrowing of the cranial foramina, including the foramen magnum. If untreated, compression of cranial nerves can lead to disabling conditions such as facial palsy, blindness, or deafness (conductive and/or sensorineural hearing loss) as cranial hyperostosis and sclerosis progress [Beighton et al 1979, Richards et al 1996]. Nasal obstruction and mandibular hyperostosis affect speech modulation.

Associated Chiari I malformation can lead to severe headaches [Day et al 1997].

Development of dentition may be delayed and teeth may fail to erupt as a result of hyperostosis and sclerosis of alveolar bone.

Malocclusion and anterior cross-bite can be caused by jaw overgrowth [Hayashibara et al 2000].

Life expectancy. Autosomal dominant CMD has typically a less severe prognosis than the autosomal recessive form (see Differential Diagnosis). Expressivity in simplex cases (i.e., single occurrence in a family) of CMD is highly variable.

Individuals with typical uncomplicated AD-CMD have normal life expectancy.

Individuals with severe forms of CMD (mostly attributed to autosomal recessive inheritance) can have reduced life expectancy as a result of compression of the foramen magnum.

Genotype-Phenotype Correlations

No genotype-phenotype correlation has been reported.

The phenotypic severity (expressivity) in AD-CMD is variable even among affected members of the same family.

Penetrance

Penetrance is close to 100% in both genders. Males and females are equally affected.

Prevalence

CMD is very rare. No epidemiology has been established.

Differential Diagnosis

Autosomal recessive craniometaphyseal dysplasia (AR-CMD). A potential locus for the autosomal recessive form of CMD is at chromosome 6q21-q22 [Iughetti et al 2000]. This localization is based on one family only. Individuals with severe forms of CMD (mostly attributed to autosomal recessive inheritance) can have reduced life expectancy as a result of compression of the foramen magnum.

Pyle disease is an autosomal recessive form of metaphyseal dysplasia with little or no involvement of the cranial bones. The gene(s) in which mutation is causative are unknown.

Braun-Tinschert type of metaphyseal dysplasia is inherited in an autosomal dominant manner. The gene(s) in which mutation is causative are unknown [Braun et al 2001].

Craniodiaphyseal dysplasia (CDD). Cranial and facial thickening are generally more severe than in CMD. Diaphyses of long bones are generally expanded; flaring of the metaphyses is mild or not observed. The long bones are cylindrical in shape. CDD may be associated with intellectual disability. The mode of inheritance is thought to be autosomal recessive; the gene(s) in which mutation is causative are unknown.

Frontometaphyseal dysplasia (FMD). Skeletal findings are frontal bone hyperostosis and metaphyseal dysplasia similar to those seen in Pyle disease (metaphyseal dysplasia). FMD is one of the otopalatodigital spectrum disorders, caused by mutations in FLNA. Inheritance is X-linked.

Osteopathia striata with cranial sclerosis (OSCS). Longitudinal striations of sclerotic long bones in combination with osteosclerosis of cranial and facial bones are characteristic. Inheritance is X-linked dominant, with likely genetic heterogeneity. OSCS is caused by mutations in WTX [Jenkins et al 2009].

SOST-related sclerosing bone dysplasias (including sclerosteosis and van Buchem disease) are allelic disorders that share progressive skeletal overgrowth. Distinctive facial features including asymmetric mandibular hypertrophy, frontal bossing, and midface hypoplasia are usually apparent by mid-childhood. Hyperostosis of the skull results in narrowing of the foramina causes entrapment of the seventh cranial nerve often leading to facial palsy and entrapment of the eighth cranial nerve often resulting in deafness in mid-childhood. In sclerosteosis, hyperostosis of the calvarium reduces intracranial volume, increasing the risk for potentially lethal elevation of intracranial pressure in adulthood. Survival of individuals with sclerosteosis into old age is unusual. The manifestations of van Buchem disease are generally milder than sclerosteosis and syndactyly is absent. Mutations in SOST, the gene encoding sclerostin, the bone morphogenetic protein (BMP) antagonist, are causative. Inheritance of both disorders is autosomal recessive.

Autosomal dominant osteopetrosis type 1, characterized by cranial sclerosis and high bone mass without increased fragility, may be caused by mutations in LRP5.

Management

Evaluations Following Initial Diagnosis

To establish the extent of disease in an individual diagnosed with autosomal dominant craniometaphyseal dysplasia (AD- CMD), the following evaluations are recommended:

  • Radiologic assessment
  • Audiologic assessment
  • Ophthalmologic examination
  • Neurologic examination
  • Otolaryngologic evaluation
  • Endocrinologic tests to assess bone metabolism
  • Dental evaluation

Craniofacial teams, often associated with pediatric hospitals, may offer a full evaluation of a patient including psychological assessment and speech therapy.

Treatment of Manifestations

Treatment consists primarily of surgical intervention. Compression of a nerve canal or narrowed foramen magnum can be surgically treated.

Severe bony overgrowth of facial bones and nasal, forehead, and cranial regions can be contoured. However, surgical procedures can be technically difficult and bone regrowth is common. As severe complications have occurred, surgery is considered for conservative purposes to relieve severe symptoms caused by cranial nerve compression.

Surveillance

Because progressive thickening of craniofacial bones continues throughout life, regular neurologic evaluation, hearing assessment, and ophthalmologic examination are required for early diagnosis and management of complications of narrowing of the cranial foramina, including the foramen magnum.

The frequency of neurologic evaluations depends on the individual's history of skeletal changes.

Evaluation of Relatives at Risk

See Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling purposes.

Therapies Under Investigation

Treatment with calcitriol, a stimulator of bone resorption, has not demonstrated long-term success. Calcitriol with a low-calcium diet to stimulate bone resorption by promoting osteoclast formation has been reported to improve facial paralysis but has no effect on metaphyseal deformity [Key et al 1988].

Search ClinicalTrials.gov for access to information on clinical studies for a wide range of diseases and conditions.

Other

Calcitonin has been thought to be effective because of its inhibitory effect on bone turnover. However, previous case reports found calcitonin therapy to be ineffective in treating hyperplasia of craniofacial bones in persons with CMD [Fanconi et al 1988, Haverkamp et al 1996].

Genetic Counseling

Genetic counseling is the process of providing individuals and families with information on the nature, inheritance, and implications of genetic disorders to help them make informed medical and personal decisions. The following section deals with genetic risk assessment and the use of family history and genetic testing to clarify genetic status for family members. This section is not meant to address all personal, cultural, or ethical issues that individuals may face or to substitute for consultation with a genetics professional. —ED.

Mode of Inheritance

Autosomal dominant craniometaphyseal dysplasia (AD- CMD) is inherited in an autosomal dominant manner.

Risk to Family Members

Parents of a proband

  • Most individuals diagnosed with autosomal dominant CMD have an affected parent.
  • A proband with autosomal dominant CMD may have the disorder as the result of a new gene mutation. The proportion of cases caused by de novo mutations is very low. Statistical data are not available.
  • If the disease-causing mutation found in the proband cannot be detected in the DNA of either parent, two possible explanations are germline mosaicism in a parent or a de novo mutation in the proband. The risk to the sibs of the proband depends on the probability of germline mosaicism in a parent of the proband and the spontaneous mutation rate of ANKH. Although no instances of germline mosaicism have been reported, it remains a possibility.
  • Recommendations for the evaluation of parents of a proband with an apparent de novo mutation include mutation analysis of ANKH. Evaluation of parents may determine that one is affected but has escaped previous diagnosis because of failure by health care professionals to recognize the syndrome and/or a milder phenotypic presentation. Therefore, an apparently negative family history cannot be confirmed until appropriate evaluations have been performed.

Note: (1) Although most individuals diagnosed with autosomal dominant CMD have an affected parent, the family history may appear to be negative because of failure to recognize the disorder in family members, early death of the parent before the onset of symptoms, or late onset of the disease in the affected parent. (2) If the parent is the individual in whom the mutation first occurred s/he may have somatic mosaicism for the mutation and may be mildly/minimally affected.

Sibs of a proband

  • The risk to the sibs of the proband depends on the genetic status of the proband's parents.
  • If a parent of the proband is affected, the risk to the sibs is 50%.
  • When the parents are clinically unaffected, the risk to the sibs of a proband appears to be low.

Offspring of a proband. Each child of an individual with autosomal dominant CMD has a 50% chance of inheriting the mutation.

Other family members of a proband. The risk to other family members depends on the status of the proband's parents. If a parent is affected, his or her family members may be at risk.

Related Genetic Counseling Issues

Mode of inheritance in simplex cases (i.e., a single occurrence in a family) cannot be determined by phenotype alone. If molecular genetic testing identifies a heterozygous disease-causing ANKH mutation, the diagnosis of AD-CMD is established.

Considerations in families with an apparent de novo mutation. When neither parent of a proband with an autosomal dominant condition has clinical evidence of the disorder, it is likely that the proband has a de novo mutation. However, possible non-medical explanations including alternate paternity or maternity (e.g., with assisted reproduction) or undisclosed adoption could also be explored.

Family planning

  • The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.
  • It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected or at risk.

DNA banking is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, mutations, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.

Prenatal Testing

If the disease-causing mutation has been identified in the family, prenatal diagnosis for pregnancies at increased risk is possible by analysis of DNA extracted from fetal cells obtained by amniocentesis (usually performed at ~15-18 weeks’ gestation) or chorionic villus sampling (usually performed at ~10-12 weeks’ gestation).

Note: Gestational age is expressed as menstrual weeks calculated either from the first day of the last normal menstrual period or by ultrasound measurements.

Preimplantation genetic diagnosis (PGD) may be an option for some families in which the disease-causing mutation has been identified.

Resources

GeneReviews staff has selected the following disease-specific and/or umbrella support organizations and/or registries for the benefit of individuals with this disorder and their families. GeneReviews is not responsible for the information provided by other organizations. For information on selection criteria, click here.

  • AboutFace International
    123 Edward Street
    Suite 1003
    Toronto Ontario M5G 1E2
    Canada
    Phone: 800-665-3223 (toll-free); 416-597-2229
    Fax: 416-597-8494
    Email: info@aboutfaceinternational.org
  • American Society for Deaf Children (ASDC)
    800 Florida Avenue Northeast
    #2047
    Washington DC 20002-3695
    Phone: 800-942-2732 (Toll-free Parent Hotline); 866-895-4206 (toll free voice/TTY)
    Fax: 410-795-0965
    Email: info@deafchildren.org; asdc@deafchildren.org
  • Children's Craniofacial Association (CCA)
    13140 Coit Road
    Suite 517
    Dallas TX 75240
    Phone: 800-535-3643 (toll-free); 214-570-9099
    Fax: 214-570-8811
    Email: contactCCA@ccakids.com
  • National Association of the Deaf (NAD)
    8630 Fenton Street
    Suite 820
    Silver Spring MD 20910
    Phone: 301-587-1788; 301-587-1789 (TTY)
    Fax: 301-587-1791
    Email: nad.info@nad.org
  • International Skeletal Dysplasia Registry
    Cedars-Sinai Medical Center
    116 North Robertson Boulevard, 4th floor (UPS, FedEx, DHL, etc)
    Pacific Theatres, 4th Floor, 8700 Beverly Boulevard (USPS regular mail only)
    Los Angeles CA 90048
    Phone: 310-423-9915
    Fax: 310-423-1528

Molecular Genetics

Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. —ED.

Table A. Craniometaphyseal Dysplasia, Autosomal Dominant: Genes and Databases

Gene SymbolChromosomal LocusProtein NameLocus SpecificHGMD
ANKH5p15​.2Progressive ankylosis protein homologANKH @ LOVDANKH

Data are compiled from the following standard references: gene symbol from HGNC; chromosomal locus, locus name, critical region, complementation group from OMIM; protein name from UniProt. For a description of databases (Locus Specific, HGMD) to which links are provided, click here.

Table B. OMIM Entries for Craniometaphyseal Dysplasia, Autosomal Dominant (View All in OMIM)

123000CRANIOMETAPHYSEAL DYSPLASIA, AUTOSOMAL DOMINANT; CMDD
605145ANK, MOUSE, HOMOLOG OF; ANKH

Normal allelic variants. ANKH has 12 exons and an mRNA transcript encompassing 8.2 kb.

Pathologic allelic variants. At least 12 mutations in exons 7, 8, 9, and 10 affecting seven amino acids are known [Nurnberg et al 2001, Reichenberger et al 2001, Kornak et al 2010, Zajac et al 2010]. Most common mutations are one-amino acid deletions. Other mutations are one-amino acid insertions, point mutations, and deletions of several amino acids. Most mutations occur in presumed intracellular domains of the transmembrane loop structure.

Normal gene product. ANKH encodes a 492-amino acid protein, the progressive ankylosis protein homolog, which is a multi-span transmembrane protein located at the outer cell membrane. Its primary known function is the transport of intracellular pyrophosphate into the extracellular matrix. Pyrophosphate is a regulator of matrix (bone) mineralization. The protein sequence of the progressive ankylosis protein homolog is highly conserved among vertebrate animals.

Abnormal gene product. Progressive ankylosis protein homolog carrying an ANKH mutation known to cause craniometaphyseal dysplasia most likely has a reduced ability to transport intracellular pyrophosphate from osteoblasts to the bone matrix [Ho et al 2000].

An animal model for CMD has been generated to study the function of mutant ANKH. The model suggests that the function of osteoblasts and osteoclasts are affected [Chen et al 2009].

References

Literature Cited

  1. Baynam G, Goldblatt J, Schofield L. Craniometaphyseal dysplasia and chondrocalcinosis cosegregating in a family with an ANKH mutation. Am J Med Genet A. 2009;149A:1331–3. [PubMed: 19449425]
  2. Beighton P, Hamersma H, Horan F. Craniometaphyseal dysplasia--variability of expression within a large family. Clin Genet. 1979;15:252–8. [PubMed: 421364]
  3. Braun HS, Nurnberg P, Tinschert S. Metaphyseal dysplasia: a new autosomal dominant type in a large German kindred. Am J Med Genet. 2001;101:74–7. [PubMed: 11343343]
  4. Chen IP, Wang CJ, Strecker S, Koczon-Jaremko B, Boskey A, Reichenberger EJ. Introduction of a Phe377del mutation in ANK creates a mouse model for craniometaphyseal dysplasia. J Bone Miner Res. 2009;24:1206–15. [PMC free article: PMC2697624] [PubMed: 19257826]
  5. Cheung VG, Boechat MI, Barrett CT. Bilateral choanal narrowing as a presentation of craniometaphyseal dysplasia. J Perinatol. 1997;17:241–3. [PubMed: 9210083]
  6. Day RA, Park TS, Ojemann JG, Kaufman BA. Foramen magnum decompression for cervicomedullary encroachment in craniometaphyseal dysplasia: case report. Neurosurgery. 1997;41:960–4. [PubMed: 9316062]
  7. Fanconi S, Fischer JA, Wieland P, Giedion A, Boltshauser E, Olah AJ, Landolt AM, Prader A. Craniometaphyseal dysplasia with increased bone turnover and secondary hyperparathyroidism: therapeutic effect of calcitonin. J Pediatr. 1988;112:587–91. [PubMed: 3351685]
  8. Gorlin RJ, Cohen MM Jr, Hennekam RCM. Syndromes of the Head and Neck. New York, NY: Oxford Press; 2001.
  9. Haverkamp F, Emons D, Straehler-Pohl HJ, Zerres K. Craniometaphyseal dysplasia as a rare cause of a severe neonatal nasal obstruction. Int J Pediatr Otorhinolaryngol. 1996;34:159–64. [PubMed: 8770684]
  10. Hayashibara T, Komura T, Sobue S, Ooshima T. Tooth eruption in a patient with craniometaphyseal dysplasia: case report. J Oral Pathol Med. 2000;29:460–2. [PubMed: 11016689]
  11. Ho AM, Johnson MD, Kingsley DM. Role of the mouse ank gene in control of tissue calcification and arthritis. Science. 2000;289:265–70. [PubMed: 10894769]
  12. Iughetti P, Alonso LG, Wilcox W, Alonso N, Passos-Bueno MR. Mapping of the autosomal recessive (AR) craniometaphyseal dysplasia locus to chromosome region 6q21-22 and confirmation of genetic heterogeneity for mild AR spondylocostal dysplasia. Am J Med Genet. 2000;95:482–91. [PubMed: 11146471]
  13. Jackson WP, Albright F, Drewry G, Hanelin J, Rubin MI. Metaphyseal dysplasia, epiphyseal dysplasia, diaphyseal dysplasia, and related conditions. I. Familial metaphyseal dysplasia and craniometaphyseal dysplasia; their relation to leontiasis ossea and osteopetrosis; disorders of bone remodeling. AMA Arch Intern Med. 1954;94:871–85. [PubMed: 13217486]
  14. Jenkins ZA, van Kogelenberg M, Morgan T, Jeffs A, Fukuzawa R, Pearl E, Thaller C, Hing AV, Porteous ME, Garcia-Miñaur S, Bohring A, Lacombe D, Stewart F, Fiskerstrand T, Bindoff L, Berland S, Adès LC, Tchan M, David A, Wilson LC, Hennekam RC, Donnai D, Mansour S, Cormier-Daire V, Robertson SP. Germline mutations in WTX cause a sclerosing skeletal dysplasia but do not predispose to tumorigenesis. Nat Genet. 2009;41:95–100. [PubMed: 19079258]
  15. Key LL Jr, Volberg F, Baron R, Anast CS. Treatment of craniometaphyseal dysplasia with calcitriol. J Pediatr. 1988;112:583–7. [PubMed: 3351684]
  16. Kornak U, Brancati F, Le Merrer M, Lichtenbelt K, Hohne W, Tinschert S, Garaci FG, Dallapiccola B, Nurnberg P. Three novel mutations in the ANK membrane protein cause craniometaphyseal dysplasia with variable conductive hearing loss. Am J Med Genet A. 2010;152A:870–4. [PubMed: 20358596]
  17. Lamazza L, Messina A, D'Ambrosio F, Spink M, De Biase A. Craniometaphyseal dysplasia: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009;107:e23–7. [PubMed: 19426903]
  18. Malkin I, Ermakov S, Kobyliansky E, Livshits G. Strong association between polymorphisms in ANKH locus and skeletal size traits. Hum Genet. 2006;120:42–51. [PubMed: 16724232]
  19. Millard DR Jr, Maisels DO, Batstone JH, Yates BW. Craniofacial surgery in craniometaphyseal dysplasia. Am J Surg. 1967;113:615–21. [PubMed: 6021432]
  20. Nurnberg P, Thiele H, Chandler D, Hohne W, Cunningham ML, Ritter H, Leschik G, Uhlmann K, Mischung C, Harrop K, Goldblatt J, Borochowitz ZU, Kotzot D, Westermann F, Mundlos S, Braun HS, Laing N, Tinschert S. Heterozygous mutations in ANKH, the human ortholog of the mouse progressive ankylosis gene, result in craniometaphyseal dysplasia. Nat Genet. 2001;28:37–41. [PubMed: 11326272]
  21. Pendleton A, Johnson MD, Hughes A, Gurley KA, Ho AM, Doherty M, Dixey J, Gillet P, Loeuille D, McGrath R, Reginato A, Shiang R, Wright G, Netter P, Williams C, Kingsley DM. Mutations in ANKH cause chondrocalcinosis. Am J Hum Genet. 2002;71:933–40. [PMC free article: PMC378546] [PubMed: 12297987]
  22. Puliafito CA, Wray SH, Murray JE, Boger WP. Optic atrophy and visual loss in craniometaphyseal dysplasia. Am J Ophthalmol. 1981;92:696–701. [PubMed: 7304697]
  23. Reichenberger E, Tiziani V, Watanabe S, Park L, Ueki Y, Santanna C, Baur ST, Shiang R, Grange DK, Beighton P, Gardner J, Hamersma H, Sellars S, Ramesar R, Lidral AC, Sommer A, Raposo do Amaral CM, Gorlin RJ, Mulliken JB, Olsen BR. Autosomal dominant craniometaphyseal dysplasia is caused by mutations in the transmembrane protein ANK. Am J Hum Genet. 2001;68:1321–6. [PMC free article: PMC1226118] [PubMed: 11326338]
  24. Richards A, Brain C, Dillon MJ, Bailey CM. Craniometaphyseal and craniodiaphyseal dysplasia, head and neck manifestations and management. J Laryngol Otol. 1996;110:328–38. [PubMed: 8733453]
  25. Sheppard WM, Shprintzen RJ, Tatum SA, Woods CI. Craniometaphyseal dysplasia: a case report and review of medical and surgical management. Int J Pediatr Otorhinolaryngol. 2003;67:71–7. [PubMed: 12560153]
  26. Taylor DB, Sprague P. Dominant craniometaphyseal dysplasia--a family study over five generations. Australas Radiol. 1989;33:84–9. [PubMed: 2712793]
  27. Tsui FW, Tsui HW, Cheng EY, Stone M, Payne U, Reveille JD, Shulman MJ, Paterson AD, Inman RD. Novel genetic markers in the 5'-flanking region of ANKH are associated with ankylosing spondylitis. Arthritis Rheum. 2003;48:791–7. [PubMed: 12632434]
  28. Tsui HW, Inman RD, Paterson AD, Reveille JD, Tsui FW. ANKH variants associated with ankylosing spondylitis: gender differences. Arthritis Res Ther. 2005;7:R513–25. [PMC free article: PMC1174945] [PubMed: 15899038]
  29. Williams CJ, Pendleton A, Bonavita G, Reginato AJ, Hughes AE, Peariso S, Doherty M, McCarty DJ, Ryan LM. Mutations in the amino terminus of ANKH in two US families with calcium pyrophosphate dihydrate crystal deposition disease. Arthritis Rheum. 2003;48:2627–31. [PubMed: 13130483]
  30. Yamamoto T, Kurihara N, Yamaoka K, Ozono K, Okada M, Yamamoto K, Matsumoto S, Michigami T, Ono J, Okada S. Bone marrow-derived osteoclast-like cells from a patient with craniometaphyseal dysplasia lack expression of osteoclast-reactive vacuolar proton pump. J Clin Invest. 1993;91:362–7. [PMC free article: PMC330035] [PubMed: 7678608]
  31. Zajac A, Baek SH, Salhab I, Radecki MA, Kim S, Hakonarson H, Nah HD. Novel ANKH mutation in a patient with sporadic craniometaphyseal dysplasia. Am J Med Genet A. 2010;152A:770–6. [PMC free article: PMC2944898] [PubMed: 20186813]

Chapter Notes

Revision History

  • 2 November 2010 (me) Comprehensive update posted live
  • 27 August 2007 (me) Review posted to live Web site
  • 25 May 2007 (er) Original submission
Copyright © 1993-2014, University of Washington, Seattle. All rights reserved.

For more information, see the GeneReviews Copyright Notice and Usage Disclaimer.

For questions regarding permissions: ude.wu@tssamda.

Bookshelf ID: NBK1461PMID: 20301634
PubReader format: click here to try

Views

  • PubReader
  • Print View
  • Cite this Page
  • Disable Glossary Links

Tests in GTR by Gene

Related information

  • MedGen
    Related information in MedGen
  • OMIM
    Related OMIM records
  • PMC
    PubMed Central citations
  • PubMed
    Links to pubmed
  • Gene
    Gene records cited in chapters on the NCBI bookshelf. Links are provided by the authors or the NCBI Bookshelf staff.

Related citations in PubMed

See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...